Incidence of T2DM (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
no estimate extracted
2 participants
GRADE not reported
Metformin Diagnostic criteria: 2 studies applied the WHO 1999 criteria for 'prediabetes' (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a; Zeng 2013) · people at increased risk for developing type 2 diabetes
Summary of findings: pioglitazone monotherapy showed no clear difference in metformin Diagnostic criteria: 2 studies applied the WHO 1999… compared with another pharmacological glucose‐lowering monotherapy (low certainty).
1 finding from 1 review
Acarbose Diagnostic criteria: 1 study applied the WHO 1999 criteria for prediabetes (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Repaglinide Diagnostic criteria: 1 study applied the ADA 2010 criteria (FPG ≥ 5.6 mmol/L and < 6.9 mmol/L and 2‐h glucose ≥ 7.8 mmol/L or < 11.0 mmol/L after a 75 g OGTT; Zhang 2007) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All cause mortality · people with cancer who have febrile neutropenia
beta‐lactam monotherapy showed no clear difference in all cause mortality compared with beta‐lactam‐aminoglycoside combination therapy (high certainty).
1 finding from 1 review
Any nephrotoxicity ‐ Ag dosing regimen (Copy) · people with cancer who have febrile neutropenia
beta‐lactam monotherapy leads to lower any nephrotoxicity ‐ Ag dosing regimen (Copy) compared with beta‐lactam‐aminoglycoside combination therapy (high certainty).
1 finding from 1 review
Clinical failure—same beta lactam Antibiotic modifications · people with cancer who have febrile neutropenia
beta‐lactam monotherapy probably leads to higher treatment failure ‐ same beta‐lactam compared with beta‐lactam‐aminoglycoside combination therapy (moderate certainty).
1 finding from 1 review
Treatment failure ‐ different beta‐lactam · people with cancer who have febrile neutropenia
beta‐lactam monotherapy may leads to lower treatment failure ‐ different beta‐lactam compared with beta‐lactam‐aminoglycoside combination therapy (low certainty).
1 finding from 1 review
All‐cause mortality · patients with stable angina pectoris
Ranolazine (monotherapy) showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Quality of life Scale: 0 to 100 · patients with stable angina pectoris
1 finding from 1 review
AMI incidence · patients with stable angina pectoris
Ranolazine (monotherapy) showed no clear difference in AMI incidence compared with placebo (low certainty).
1 finding from 1 review
Angina episodes frequency · patients with stable angina pectoris
1 finding from 1 review
Adverse events incidence · patients with stable angina pectoris
It is very uncertain whether ranolazine (monotherapy) changes adverse events incidence compared with placebo (very low certainty).
1 finding from 1 review
Cardiovascular mortality · patients with stable angina pectoris
Ranolazine (monotherapy) showed no clear difference in cardiovascular mortality compared with placebo (low certainty).
1 finding from 1 review
Non‐cardiovascular mortality ‐ not reported · patients with stable angina pectoris
The review found no eligible studies for this question.
1 finding from 1 review
Efficacy: change in scores from baseline to endpoint (12 weeks) on symptom rating scales in the treatment of manic and mixed episodes Lower scores indicate improvement · adults with acute affective episodes in bipolar disorder
1 finding from 1 review
Change in depressive symptoms · adults with acute affective episodes in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability. Participants experiencing troublesome adverse effects of any nature · adults with acute affective episodes in bipolar disorder
Topiramate as monotherapy showed no clear difference in acceptability with topiramate (12 weeks) Number of participants… compared with an alternative drug (low certainty).
1 finding from 1 review
Response to treatment with topiramate. Number of participants experiencing a 50% reduction or greater in mean score from baseline to end of treatment on symptom rating scales in manic and mixed episodes · adults with acute affective episodes in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found